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Periodontitis and Rheumatoid Arthritis:
A Review
P.M. Bartold,* R.l.  Marshall , I  and D.R. Haynesf
Periodontit is and rheumatoid arthrit is (RA) appear to share
many pathologic features. In this review, the common patho-
logic mechanisms of these two common chronic conditions
are explored. Emerging evidence now suggests a strong rela-
tionship between the extent and severity of periodontal disease
and RA. While this relationship is unlikely to be causal, it is clear
that individuals with advanced RA are more l ikely to experience
more significant periodontal problems compared to their non-
RA counterparts, and vice versa. A case is made that these
two diseases could be very closely related through common un-
derlying dysfunction of fundamental inflammatory mecha-
nisms. The nature of such dysfunction is sti l l  unknown.
Nonetheless, there is accruing evidence to support the notion
that both conditions manifest as a result of an imbalance be-
tween proinflammatory and anti-inflammatory cytokines. As
a result, new treatment strategies are expected to emerge for
both diseases that may target the inhibit ion of proinflammatory
cytokines and destructive proteases. The clinical implications
of the current data dictate that patients with RA should be care-
fully screened for their periodontal status. J Periodontol
2005;76:2066-2074.
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"ln fact, adult periodontitis and
rheumatoid arthritis have much in
common, so much so that I have
argued that they are really the same
disease." 1
he above bold and challenging
statement may seem to be
stretching the boundaries of con-
ventional thought too far. However,
close inspection of two of the most com-
mon chronic diseases affl icting humans
reveals remarkable similarit ies that war-
rant further investigation.
The relationship between rheumatoid
arthrit is (RA) and the progression of in-
flammatory conditions elsewhere in the
body, such as periodontit is, is controver-
sial. While a number of studies have
presented conflicting results regarding
a relationship between periodontit is and
RA, there have been recent reports sug-
gesting a significant association between
these two common chronic inflammatorv
condi t ions.2 6 In l ight  of  these repor ts ,
there is a need for further investigations
to determine whether the severity of RA
and the severity of periodontit is are inter-
related. To do this, controlled, population-
based, laboratory, and clinical (molecular
epidemiology) studies are needed to ver-
ify the immunological and biological as-
sociations between RA and periodontal
disease.
PERIODONTAL D ISEASES
The periodontal diseases range from the
relatively benign form of gingivit is to ag-
gressive periodontit is. Many of these
conditions are not only a threat to the
dentit ion, but may also be a threat to
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general health. There are reports suggesting in-
creased prevalence of diabetes, atherosclerosis,
myocardial infarction, and stroke in patients with peri-
odontaldisease.T-e Thus, the likelihood of periodontal
disease being associated with systemic diseases is be-
coming established fact. All forms of inflammatory
periodontal disease are associated with chronic in-
flammation (accumulation of B and T lymphocytes
as well as monocytes and neutrophils) , resulting in de-
struction of the periodontal ligament and bone' lf left
untreated, significant tissue damage occurs, and the
affected teeth can become loose and may be lost if
the disease continues to be active. What is particularly
curious about this disease is the great variability in
presentation. Because of its multifactorial nature,
which is modified by systemic, environmental, and
microbiological factors, not all individuals are af-
fected to the same degree despite the ubiquitous pres-
ence of dental plaque.
RHEUMATOID ARTHRITIS
Rheumatoid arthritis is also a chronic destructive in-
flammatory diseasel0 characterized by the accumula-
tion and persistence of an inflammatory infiltrate in
the synovial membrane that leads to synovitis and
the destruction of the joint architecture resulting in
impaired function. As a systemic disease, RA has
extra-articular manifestations in systems such as the
pulmonary, ocular, vascular, and other organs or
structures that may be affected by the inflammatory
process. The current paradigm for RA includes an ini-
tiating event (possibly a microbial exposure or a puta-
tive autoantigen) leading to significant synovial
inflammation and tissue destruction. As for periodon-
titis, there is an accumulation of inflammatory cells (T
and B lymphocytes, neutrophils, and monocytes), tis-
sue edema, endothelial cell proliferation, and matrix
degradation. RA is also modified by systemic, genetic,
and environmental variables.
SIMILARITIES BETWEEN RHEUMATOID
ARTHRITIS AND PERIODONTITIS
Natural Historg
Periodontal disease. Natural history studies of
periodontal disease in humans indicate the presence
of three distinct subpopulations: 11 1) no progression
of periodontal disease, in which around 10% of the
population manifest vdry little or no disease which is
of no particular consequence to the dentition; 2) mod-
erate progression, affecting around B0% of the popu-
lation and representing a very slowly progressing form
of disease that generally can be easily managed via
routine therapies; and 3) rapid progression, affecting
approximately 8% of individuals whereby extensive
periodontal destruction occurs which can be very dif-
ficult to control.
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From the natural history studies of RA and peri-
odontitis, it has been observed that certain RA and
periodontitis populations are characterized by a
particular type of patient who will experience dis-
ease progression irrespective of any treatment pro-
vided. Whether the RA grouP, in which disease
progression seems uncontrolled even after compre-
hensive treatment, is the same group that is suscepti-
ble to develop severe forms of periodontal disease
remains to be established and is, indeed, a major
thesis of this review.
Rheumatoid arthritis. At least three types of dis-
ease manifestation can also be observed in RA pop-
ulations: 7) seltlimited: in these cases individuals
originally presenting for RA have no evidence of
disease 3 to 5 years later;12 2) eastlg controlled: Ihe
disease is relatively easily controlled with only non-
steroidal anti-inflammatory drugs (NSAIDs);13 ) pro'
gressiue: these patients generally require second-line
drugs, which often still do not fully control the dis-
e a s e . 1 4 , l 5
Etiologic Factors
Periodontitis. The periodontal diseases are well
recognized as classic examples of chronic inflamma-
tory diseases resulting from the induction of host in-
flammatory responses to the subgingival biofilm'
Gingivitis is typically characterized as a robust in-
flammatory response confined mainly to the superfi-
cial gingival connective tissues and is a relatively
nonspecific response to a nonspecific accumulation
of dental plaque. How gingivitis progresses to peri-
odontitis is stil l unclear.l6
Periodontitis, on the other hand, appears to be
a more specific inflammatory response to specific
periodontal pathogens residing in the subgingival bio-
film. Within the conditions known as periodontitis,
there is considerable variability in terms of clinical
manifestation and disease progression rates' This var-
iability can be attributed to differences in composition
of the subgingival microbial flora, as well as factors
that modify the host response to the microbial chal-
lenge. Nonetheless, it must be noted that, although
bacteria are necessary for disease initiation, they
are not sufficient to cause disease progression unless
there is an associated inflammatory response within
a suscept ible host. l6
Rheumatoid arthritis. Although the cause of RA is
unknown, it has been recognized that many different
arthritogenic stimuli activate infl ammatory resPonses
in immunogenetically susceptible hosts. Thus, stud-
ies have focused on exogenous infectious agents, en-
dogenous substances, such as connective tissue
proteins (e.g., collagens and proteoglycans), and al-
tered immunoglobulins as the causative candidates.
The concept that RA is an infectious disease has been
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considered for  over  70 years. r /  The idea that  RA pa-
tients acquire an infection that elicits an immune re-
sponse in the synovial membrane would account for
some of  the c l in ica l  features and would a lso expla in
the accumulat ion of  immunocompetent  T and B cel ls
in the Iesions. Data from different animal models dem-
onstrate that arthrit is can develop secondarily to sev-
eral different stimuli and through several different
effector pathways. If such observations are also appli-
cable to human RA, we might anticipate that different
types of infections as well as other environmental
exposures with capacity to induce excessive proin-
flammatory cytokines in genetically susceptible indi-
v iduals may a l l  potent ia l ly  contr ibute to d isease e i ther
in unison or  iso lat ion.
Are Bacteria a Common Etiologic Link Between
Periodontitis and Rheumatoi"d A rthritis?
There are a number of shared features between
microorganisms that  can induce RA in a genet ica l ly
susceptible host and the recognized periodontal
pathogens.  Nonetheless,  RA is  s t i l l  not  largely recog-
nized as a d isease resul t ing sole ly  f rom bacter ia l
chal lenge.  On the other  hand,  technological  and con-
ceptual advances have permitted the identif ication of
bacteria or groups of bacteria associated with specific
per iodonta l  d iseases. ls  Close inspect ion of  the v i ru-
lence factors of periodontal pathogens would suggest
that  such a response could be feasib le.  Thus,  the pos-
s ib i l i ty  that  ongoing per iodont i t is  could t r igger  RA in
genet ica l ly  suscept ib le indiv iduals is  p lausib le.
Notwithstanding the above, these concepts remain
speculative unti l the causative agent for RA can be de-
finit ively identif ied. To date, no infectious agents have
been identif ied as the cause of RA in humans. Indeed,
current information does not support the concept that
a single antigen is responsible for synovial inflamma-
t ion.  I t  is  possib le that  there is  no s ingle pr imary cause
of  RA and that  d i f ferent  mechanisms may indepen-
dently lead to synovial inflammation in susceptible in-
dividuals. It is important to recognize that, based on
current information, we do not propose that periodon-
tal pathogens cause, or are associated with, RA. The
main focus of our attention is directed not towards
causality but rather associations between two chronic
inflammatory conditions that may have common un-
der ly ing pathogenic mechanisms.
Immunogenetics
Periodontit is. [t has been reported that more than
50% of the variance in several features of chronic peri-
odontit is can be explained by genetic fss1..r. l9'20
Many of these interindividual variables relate ro sever-
ity of periodontal destruction, and other inflammatory
responses are attributed partly to the amount and type
of  cytok ines that  ind iv iduals produce.2 l  Whi le the
HLA-DR phenotype is not particularly strong for peri-
odontit is, there is a report indicating that it is an
important component of the genetic susceptibil i ty to
some forms of  th is  d isease.22 In addi t ion,  polymor-
phisms in the in ter leukin-  1 g ( lL-  1 B)  gene c luster  have
been shown to have a significant correlation with
some forms of periodontit is in certain populations.23
Rheumatoid Arthrit is. Family studies and studies
on monozygotic and dizygotic twins have shown
that RA has several features indicative of a complex
genet ic  d isease inc luding genet ic  var iance,  incom-
plete penetrance, and multiple gene involvement.24
For RA, the strongest genetic associations are found
wi th in the HLA genes.23 Using DNA sequencing and
molecular-based typ ing,  i t  has been demonstrated
that the disease-conferring portion of the D region is
confined to a short sequence within the third hyper-
var iable region of  HLA-DRB1 gene which inc ludes
the amino acid positions 67 through 74.2s'2o 11-,t"
HLA genes and gender constitute about 30% ofthe ge-
netic risk in RA, while other genetic factors such as
cytok ine genes,  germl ine genes,  and T-cel l  receptors
also account for some of the genetic predisposition
t o  R A . 1 o
Effector Mechanisms of Tissue Destruction in
Rheumatoid Arthritis and Periodontitis
There is almost universal acceptance that a variety of
cytok ines and matr ix  metal loprote inases (MMPs) are
upregulated and int imate ly  involved in the pathogen-
esis of both periodontit is and RA; many of these effec-
tor  molecules appear to be common to both d iseases.
The task now is to identify the specific cytokines, their
concentrations, the cells they affect in vivo, the stages
in which they are active, and the role and concentra-
tions of their inhibitors. While the effects of cytokines
on normal  ce l lu lar  process are important ,  i t  is  thei r
purported roles in pathophysiology that may result
from excessive production, dysregulation, or inade-
quate inhib i t ion that  have gained most  at tent ion. l
Very simply, cytokines can be classified into func-
t ional  groups based on the cel ls  of  or ig in,  and a l l  major
types have been identif ied and located in inflamed
synovia l  and per iodonta l  t issues.
Periodontit is has very similar cytokine profi les to
p4,27'28 consisting of persistent high levels of proin-
f lammatory cytok ines,  inc luding lL-  1B and tumor
necrosis  factor-a lpha (TNF-ct) ,  and low levels of  cyto-
kines which suppress the immunoinflammatory re-
sponse such as IL-  10 and t ransforming growth
factor-B (TGF B). These cytokines, together with
low levels of t issue inhibitors of metalloproteinases
(TIMPs) and high levels of MMPs and prostaglandin E2
(PGE2), are associated with the active stages of peri-
odontit is.
The destruction of soft and hard tissues seen in RA is
also the result of not only a large number of cytokines
d
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but also the sustained presence of other effector mol-
ecules released by resident and migrating cells. To-
gether, these soluble mediators of inflammation are
able to induce degradation of collagen and proteogly-
cans either through direct or indirect means. Produc-
tionof the arachidonic acid metabolite PGE2 as well as
the release of neutrophil-associated enzymes, such as
neutrophil elastase and B-glucuronidase, together
with the secretion of matrix metalloproteinases by
macrophages and synoviocytes, all contribute signif-
icantly to the pathogenesis of RA.
Formulation of the Hgpothesis
On the basis of the above considerable similarities be-
tween the pathological and clinical features of RA and
periodontitis (especially in the advanced and aggres-
sive forms of these diseases), we have proposed that
in some susceptible individuals, there are common
features of an underlying and presently unknown dys-
regulation of the inflammatory mechanism which pre-
disposes these individuals to advanced, aggressive,
and severe forms of either disease.
Studies on Relationships Between Periodontitis
and Rheumatoid Arthritis
To date, very few studies have examined the associa-
tion between RA and periodontal disease, and the
results have often been conflicting. For example,
Finnish studies found no correlation between peri-
odontal disease and arthritis,2e while others3,30 sug-
gest a higher prevalence of periodontal bone loss in
RA. A major reason for these discrepancies relates
to the lack of uniformity in classifying the various
forms of periodontal disease and RA. Indeed most
of the early studies,3'29-31 failed to take into account
the various forms of RA and periodontal disease
and, as a result, grouped all subjects as either having
RA or periodontal disease with little or no regard for
subclassification for more detailed analyses. In light
of these limitations, it is clear there is a need to
re-examine the extent of the association between
specific types of RA and periodontal disease. In par-
ticular, it is our thesis that the more aggressive or
severe forms of periodontal disease and RA will show
a very close correlation in terms of coexistence.
ln our first pilot study,6 investigating self-reported
disease xperience, the prevalence of moderate to
severe periodontitis was significantly elevated in in-
dividuals with RA (uhadjusted relative risk of 4.7).
In addition, the converse was also true in that peri-
odontitis patients had a higher prevalence of RA com-
pared to the general population (unadjusted relative
r isk of 1.5).
In a subsequent study, 65 patients attending a
rheumatology clinic were studied for their level of peri-
odontitis and RA.2 A control group consisted of age-
and gender-matched individuals who did not have
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RA. No differences were noted for the plaque and
bleeding indices between the control and RA groups.
The RA group did, however, have significantly more
missing teeth than the control group and a greater per-
centage of these subjects had deeper pocketing com-
pared to the controls. The percentage of alveolar bone
loss correlated positively with the principal parame-
ters of RA severity.
These two pilot studies have resulted in several sig-
nificant findings. Contrary to current dogma, RA pa-
tients do not have impaired oral hygiene (judged by
plaque and bleeding scores). Perhaps more impor-
tantly, it was noted that individuals with severe RA
are more likely to have advanced periodontitis and
vice versa. Although many RA patients take medica-
tions that can reduce periodontal destruction (i.e.,
NSAIDs and immunosuppressants), we have noted
significant periodontal destruction in these patients.
This indicates that prior to the development of RA
symptoms, the periodontitis was most likely develop-
ing and not detected. Thus, disease duration may be
a very important factor. Finally, in order to understand
the interrelationships between periodontitis and RA, it
is necessary to categorize the disease on the basis of
severity and duration (i.e., type of disease).
Recently, using an animal model, additional evi-
dence has been presented to indicate a significant re-
lationship between periodontitis and rheumatoid
arthritis.32 From this study it was reported that induc-
ing experimentalarthritis in the rat (adjuvant arthritis)
resulted in periodontal breakdown characterized
by alveolar bone loss and increased matrix metallo-
proteinase activity in adjacent gingival tissues. Inter-
estingly, all of these reactions occurred without
manipulating the oral or subgingival microflora.
Osteoclast Actioation and Vascular Damage - A
Common Pathwag in Periodontitis and
Rheumatoid Arthritis?
Most recently, studies from our laboratory (unpub-
lished data) have begun to investigate the codistribu-
tion of cytokines involved in vascular damage and
bone resorption in biopsies from graded rheumatoid
arthritis and periodontitis lesions. Since the tumor ne-
crosis factor (TNF)-like molecules and their receptors
have been shown to be involved in both processes, we
have chosen to study the receptor activator of nF-
kappa B ligand (RANKL), osteopretogerin (OPG),
and TNF-related apoptosis inducing ligand (TRAIL)
to determine at least one molecular mechanism com-
mon to both conditions.
The cell surface TNF-like molecule, RANKL and its
receptor, RANK have been shown to be key factors
regulating osteoclast formation and activation.33'34
It has been shown that when RANKL binds to RANK
on the surface of osteoclast precursors, these cells
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differentiate to form mature osteoclasts. It is now clear
that RANKL, together with macrophage-colony stim-
ulating factor (M-CSF), is required for osteoclast for-
mation. The soluble TNF "receptor-l ike" molecule,
OPG, is a natural inhibitor of RANKL.35 OPG btnds
to RANKL and prevents its l igation to RANK. The im-
portance of these molecules in regulating bone me-
tabolism has been demonstrated by transgenic and
gene knock-out studies in mice.36 Since these factors
control physiologic osteoclast formation, it is reason-
able to propose that they may also be key regulators
of pathological bone resorption.3T'38 Although
RANKL is normally provided by osteoblast-l ike cells
in bone,38'3e there are reports suggesting that lym-
phocytes present in rheumatoid tissues may be the
main source of RANKL in inflammatory arthrit is.33'40
Furthermore, CD3+ T cells from the human rheuma-
toid joint express RANKL and can promote osteoclast
formation from rodent spleen precursors.a0 In addi-
tion to lymphocyte production of RANKL, inhibit ion
of RANKL by OPG treatment in vivo reduces both
bone and carti lage destruction in a model of adjuvant
arthrit is.a I
Under certain conditions, human osteoclasts are
derived from osteoclast precursor cells present in or
near to the tissues of arthrit ic joints.a2,a3 More recent
reports in humans44,45 un4 animals4l show that
RANK/RANKL interactions may be required for oste-
oclast formation and bone resorption in the RA joint.
Accordingly, we have recently demonstrated that OPC
and RANKL are expressed in biopsies of inflamed
rheumatoid synovium and periodontit is lesions.46 In
addition, we have found (unpublished data) that an-
other l igand for OPG, TRAIL, is expressed in the both
types of t issue (although not from the same patient).
In these studies we have noted that OPC decreases
with inflammation, RANKL increases with inflamma-
tion, and TRAIL increases with inflammation. These
findings may be of considerable significance in l ight
of OPG's abil ity to block the activity of TRAIL (and
vice versa) and TRAIL's anti-inflammatory proper-
ties.aT
The production of OPG by endothelial cells may be
significant for reasons other than its effects on bone
metabolism, and there is now evidence to suggest that
OPG might also regulate endothelial cell function.
OPG has been reported to be required for endothelial
cell survival and growth.as In addition, OPG knock-out
mice have been shown to develop arterial calcif ica-
6on49,50 as well as severe osteoporosis, suggesting
that vascular endothelial expression of OPC may
have a role in vascular homeostasis.4l One of the
most unexpected findings from our recent studies of
diseased periodontal and synovial t issues was the ob-
servation that endothelial cells produce large amounts
of OPG (unpublished observations).
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ln response to proinflammatory cytokines TNF-o
and lL- 1 P, OPG mRNA expression was dramatically
enhanced, resulting in secretion of newly synthesized
OPG and a reduction in cell-associated OPG. Such
findings are consistent with our observations in vivo
for active RA and periodontit is lesions. Vascular dam-
age due to apoptosis is thought to precede vascular
calcif ication5l and contribute to atherosclerosis.52
In addi t ion,  d iabet ic  endothel ia lce l ldysfunct ion is  as-
sociated with DNA damage induced by poly (ADP-
ribose) polymerase activation. The exact cause of
endothelial cell dysfunction is not known but it is pos-
sible that molecules such as TRAIL, expressed in
nearby cells and tissues, may be important.38,53 9u,
recent binding studies confirm that OPG binds to
TRAIL, although with less affinity than RANKL, in vi-
tro, and blocks its activity (unpublished data). The fi-
nal piece of compelling evidence for the role of OPG in
vascular damage comes from the fact that OPG
knock-out mice develop vascular calcif ication. It is
significant to note that calcif ication cannot be re-
versed by systemic treatment with recombinant OPG
postpartum.5o This supports our concept that OPG
must be expressed within the endothelial cells, either
in an appropriate form or associated with other mole-
cules, and this only occurs following normal synthesis
within the healthy endothelial cells.
In l ight of the above, we propose that at least one
underlying common molecular pathway in common
between rheumatoid arthrit is and periodontit is may
lie within the RANK/OPG/TRAIL axis whereby OPG
decreases leading to decreased vascular protection.
In addition, with an increase in RANKL and TRAIL
wi th in the t issues,  not  only  is  vascular  damage pos-
sible, but significant activation of osteoclasts may
result. This proposal sti l l  awaits verif ication.
COMMON PATFIOGENESIS  _  COMMON
TREATMENT?
Current and Emerging Therapies
Currently, the mainstream "first-l ine" modes of treat-
ment for RA remain the NSAIDs such as aspirin, nap-
roxen, diclofenac, and ibuprofen. Their mechanism of
action through the inhibit ion of cyclooxygenase
(COX) synthesis produces both analgesic and antipy-
retic properties. While these medications are effective
in reducing the pain symptoms in RA, they do not sig-
nificantly alter its course.54
The use of NSAIDs for management of periodontal
disease has been studied over the past 20 years.s5-57
While the results appear promising, the widespread
clinical use of these medications to alter the course
of periodontit is has not been universal. One particular
problem with their use for the management of peri-
odontit is appears to be a "rebound" effect to baseline
following cessation of the medication.5s
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With the discovery of two COX enzymes responsi-
ble for PGE2 production, designated COX- 1 (constitu-
tively expressed) and COX-2 (inducible), a variety of
COX-2 inhibitors have been studied for their potential
to stop or slow down bone resorption. One of the first
COX-2 inhibitors developed, tenidap, has been shown
to inhibit not only cyclooxygenase and PGE2 produc-
tion but also IL-1, IL-6, and TNF-ct production. To
date, COX-2 inhibitors have not been thoroughly
studied for their potential to modify bone resorption
in periodontitis.
In contrast to the NSAIDS, which do not signifi-
cantly alter the course of RA, a newer family of med-
ications designated disease-modifying anti-rheumatic
drugs (DtvtARDs) has been developed. To be classified
as a D/vlARD. the medication must demonstrate an
ability to change the course of RA for at least 1 year
as evidenced by sustained improvement in function,
decreased synovitis, and prevention of further joint
damage.5e Examples of these medications include
parenteral gold salts, methotrexate, sulfasalazine, hy-
droxychloroquine (antimalarial drug), penicillamine,
azathioprine, and leflunomide. A major drawback in
the use of Dl4ARDs is their considerable toxicity.60'61
The use of DMARDs for the management of peri-
odontitis has been restricted largely due to the toxicity
of elevated IL-1 in inflamed tissues.T2-74 Similarly,
other studies have shown that blocking the activity
of another important inflammatory cytokine, TNF-a,
has therapeutic efficacy in RA patients.T5-78 The roles
of IL-1 and TNF antagonists in a primate model of
periodontitis have demonstrated a reduction in the
inflammatory infiltrate in close proximity to bone as
well as reduction in the formation of osteoclasts and
reduced bone loss.79
Clearly, many of these biologic agents, which tar-
get specific molecular events associated with acute
and chronic inflammation, have significant potential
to alter clinical outcomes for both RA and periodontal
disease. With the emerging understanding that RA
and periodontitis are multifactorial diseases, combi-
nation therapies that target multiple disease out-
comes are also emerging. For example, in an
animal study, it was reported that the administration
of a combination of a chemically modifiedtetracycline
(CMT- 1) plus an NSAID, such as flurbiprofen or teni-
dap, synergistically inhibited severe bone destruction
in arthritic rats, with the suppression of MMP activity in
the joints.80'81 Similar encouraging results have been
reported for periodontitis in humans.82
Notwithstanding the above, it must be recognized
that periodontitis differs in one significant way from
RA through our understanding that the subgingival
biofilm is a key etiologic factor. Unlike periodontal
disease, no specific bacterial etiology has been iden-
tified for RA. Thus, while host modification of disease
processes are possible for periodontitis, controlling
the bacteria that cause periodontal infections remains
a significant focus for periodontal treatment and pre-
vention. At best, host modification can be only an ad-
junct treatment for periodontitis. However, until an
etiologic factor can be found for RA, host modification
remains the mainstay of treatment.
CONCLUSIONS
There is no question that periodontitis and RA have
many pathologic features in common. Emerging evi-
dence suggests a strong relationship between the ex-
tent and severity of periodontal disease and RA. While
this relationship is unlikely to be causal, it is clear that
individuals with advanced RA are more likely to expe-
rience more significant periodontal problems com-
pared to their non-RA counterparts, and vice versa.
Hence, the possibility exists that both conditions re-
sult from a common underlying dysregulation of the
host inflammatory response. The precise nature of
this dysregulation remains to be established.
There is accruing evidence to support the notion
that both conditions manifest as a result of an imbal-
ance between proinflammatory and anti-inflammatory
cytokines. As a result, new treatment strategies will
emerge for both diseases that may target the inhibition
issues. However, the use of gold salts in an animal
model has shown reduced periodontal destruction.62
To date, no human studies have been performed.
Another emerging area of potential for host modu-
lation in periodontitis and rheumatoid arthritis is con-
trol of the lvlMPs that are important mediators of
,tonnective tissue breakdown in both hard and soft tis-
sues. In this regard, tetracyclines and various chemi-
analogues have been found to inhibit MMP activity
a mechanism that is independent of their antimi-
property.63,64 A number of clinical trials using
dose tetracycline to modify periodontitis have
carried out, with the most recent data indicating
low-dose doxycycline is safe and significantly ef-
65'66 5on"11'teless, it is still recommended that
data be interpreted with caution to differentiate
statistically signifi cant and clinically relevant
67 The role of MMP inhibitors in managing RA
been less well studied but promising results are
ing.68-zo In particular, a recent study has dem-
that low-dose and antimicrobial (higher)
doxycycline, when used adjunctively with meth-
, produces enhanced improvements in global
of RA severitv in humans than methotrexate
with placebo.Tl
Control of cytokines and their receptors is also
as a field of considerable promise. For ex-
, blocking the lL- 1 receptor and using gene
to deliver IL-1 receptor antagonist are two
under investigation to modulate the effect
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of proinflammatory cytokines and destructive pro_
teases.
Through a better understanding of these rwo com_
mon chronic inflammatory conditions, it is hoped that
areas of similarity can be exploited to determine the
true relationship between these diseases and com_
mon areas of treatment. Already, it can be predicted
that the periodontal status of paiients with RA should
be carefully screened.
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